Daiichi Sankyo Korea and AstraZeneca Korea announced MFDS approval of Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer and HER2-mutant metastatic NSCLC

Approval was based on results from DESTINY-Breast04 and DESTINY-Lung02 trials

DESTINY-Breast04 demonstrated significant improvement in mPFS (10.1 vs. 5.4 months) and mOS (23.4 vs. 16.8 months) with a 36% reduction in risk of death for HR+ breast cancer patients. DESTINY-Lung02 showed a 49% confirmed ORR with a mDoR of 16.8 months